- Home
- Posts
- 🍄 Trip Sheet: Compass Pathways (CMPS) clears Phase 3 hurdle with COMP360 psilocybin in treatment-resistant depression
🍄 Trip Sheet: Compass Pathways (CMPS) clears Phase 3 hurdle with COMP360 psilocybin in treatment-resistant depression
Clearmind (CMND) expands its AUD study to Tel Aviv, as Enveric (ENVB) reports its novel amylin-agonist antibody slashes food intake by 60% in obese mice.
Jun 26, 2025
One trade idea here could pay for your subscription 10x.
We don’t cover fluff. We cover ideas that move portfolios. Upgrade now, before you miss your next trade
Upgrade